By: JNCCN 360 StaffPosted: Friday, December 18, 2020 The U.S. Food and Drug Administration (FDA) recently approved the HER2-targeted monoclonal antibody margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens (one of which was for metastatic disease), according to...
Category: Breast Cancer
Post
BASKET Study – Covers multiple solid tumor cancer types
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the drug is expected to work against cancer. This study will enroll...